07668T0-1390 Rec 20000)

U.S. DEPARTMENT OF COMMERCE ATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 689290-227

04 DTO3 Rec'd PCT/PTO 3 0 NOV

U.S.APPLICATION NO. (If known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO. PCT/US03/17559

INTERNATIONAL FILING DATE 4 June 2003

PRIORITY DATE CLAIMED 4 June 2002

	·						
TITLE OF	E OF INVENTION CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY						
APPLICA	LICANT(S) Martin SHEA and Reinhard EBNER						
Applicat	licant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items	and other information:					
_							
1. 🛛	his is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2. 🗆	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3. 🖾	This express request to being national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. 🛛	The US has been elected by the expiration of 19 months from the priority date (Article 31).	e expiration of 19 months from the priority date (Article 31).					
5. 🛛	A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
	a. is attached herewith (required only if not communicated by the International Bureau).						
	b. has been communicated by the International Bureau.						
	c. 🔯 is not required, as the application was filed in the United States Receiving Office (RO/US)						
6. 🔲	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))						
	a. is attached hereto.						
	b. has been previously submitted under 35 U.S.C. 154(d)(4).	•					
7. 🖾	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
•	a. are attached hereto (required only if not communicated by the International Bureau).						
	b. have been communicated by the International Bureau.						
	c. have not been made; however, the time limit for making such amendments has NOT expired.						
	d. 🛛 have not been made and will not be made.						
8., 🗆	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C.	371 (c)(3)).					
9. 🛛	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
á0. □	An English language translation of the annexes to the International Preliminary Examination Report	ish language translation of the annexes to the International Preliminary Examination Report under					
	PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items 1	ns 11 to 20 below concern other document(s) or information included:						
11. 🔲	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12. 🔲	☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 a	ind 3.31 is included.					
13. 🔲	A FIRST preliminary amendment.						
14. 🔲	COND or SUBSEQUENT preliminary amendment.						
15. 🔲	A substitute specification.	substitute specification.					
16. 🔲	A change of power of attorney and/or address letter.	r address letter.					
17. 🔲	☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.I	-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825.					
18. 🛛	A second copy of the published international application under 35 U.S.C. 154(d)(4).	ned international application under 35 U.S.C. 154(d)(4).					
19. 🔲	econd copy of the English language translation of the international application under 35 U.S.C. 15(d)(4).						
20. 🖂	Other items or information: Sequence Listing on Diskette plus statement under 37 C.F.R. 1.821(f)						

Form PTO-1390(Rev.11-2000) page 1 of 2

U.S. APPLICATION NO. (If known see 37 6.F. 771.8	ATTORNEY'S DOCKET NUMBER 689290-227							
21. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor								
international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO and JPO \$1110.00								
International preliminary examination fee (37 CF but International Search Report prepared by the								
International preliminary examination fee (37 CF but international search fee (37 CFR 1.445(a)(2)								
International preliminary examination fee (37 CF but all claims did not satisfy provisions of PCT A								
International preliminary examination fee (37 CF and all claims satisfied provisions of PCT Article								
ENTER APPROPRIATE	\$	750.00						
Surcharge of \$130.00 for furnishing the oath or decl months from the earliest claimed priority date (37 C	⊠ 30	\$	130.00					
CLAIMS NUMBER FILED N	NUMBER EXTRA	RATE	\$					
Total Claims 36 - 20 =	16	X \$18.00	\$	288.00				
Independent Claims 9 - 3 =	6	X \$88.00	\$	528.00				
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	\$	0.00						
TOTAL OF ABOVE	CALCULATIONS	=	\$	1695.00				
Applicant claims small entity status. See 37 CFF above are reduced by 1/2	\$	848.00						
	\$	848.00						
Processing fee of \$130.00 for furnishing the English translation later than 20 30 \$ months from the earliest claimed priority date (37 CFR 1.492(f))								
	\$	848.00						
Fee for recording the enclosed assignment (37 CFR accompanied by an appropriate cover sheet (37 CFR	\$							
	TOTAL FE	ES ENCLOSED =	\$	848.00				
		ount to be inded:	\$					
	charged: \$							
	8.00 to cover the above fe							
b. Please charge my Deposit Account No. A duplicate copy of this sheet is enclose		to cover the above to	ees.					
c. Ithe Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>03-0678</u> . A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO: Date: 30 November 2004								
<u> </u>				en J. Grant				
ALAN J. GRANT Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein				•				
5 Becker Farm								
Roseland, New Jersey 07068								
	ON NUMBER							

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Martin Shea

Serial No:

PCT/US03/17559

Art Unit: Unassigned

Filed:

4 June 2003

Examiner: Unassigned

Title:

CANCER-LINKED GENE AS TARGET FOR CHEMOTHERAPY

Docket No:

689290-227

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Statement Under 37 CFR 1.821(f)

Sir:

Applicant hereby asserts that the paper Sequence Listing originally filed with this application and the sequence listing being submitted herewith in Computer Readable Form on the accompanying 3.5" diskette are the same and no new matter is being added to the application.

Respectfully submitted,

Alan J. Grant

Reg. No. 33,389

CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN

CECCHI, STEWART & OLSTEIN

5 Becker Farm Road Roseland, NJ 07068

Tel. No.: (973) 994-1700